



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : A01N 59/14, 37/16 // (A01N 59/14, 37:44, 37:40, 37:16) (A01N 37/16, 59:14, 37:44, 37:40)</p>	A1	<p>(11) International Publication Number: WO 95/02330</p> <p>(43) International Publication Date: 26 January 1995 (26.01.95)</p>
<p>(21) International Application Number: PCT/US94/07726</p> <p>(22) International Filing Date: 12 July 1994 (12.07.94)</p> <p>(30) Priority Data: 08/090,791 12 July 1993 (12.07.93) US</p> <p>(71) Applicant: STERIS CORPORATION [US/US]; 9450 Pineneedle Drive, Mentor, OH 44060 (US).</p> <p>(72) Inventors: KRALOVIC, Raymond, C.; 4774 Sherwin Drive, Willoughby, OH 44094 (US). LEVIN, David, Z.; Apartment 501, 6505 Marsol Road, Mayfield Heights, OH 44124 (US). LINDEMAN, Lorraine, D., H.; 7990 Aileen Drive, Mentor, OH 44060 (US).</p> <p>(74) Agent: KOCOVSKY, Thomas, E., Jr.; Fay, Sharpe, Beall, Fagan, Minnich & McKee, Suite 700, 1100 Superior Avenue, Cleveland, OH 44114-2518 (US).</p>	<p>(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published <i>With international search report.</i></p>	
<p>(54) Title: COLD STERILANT WITH EXTENDED ACTIVE LIFE</p>		
<p>(57) Abstract</p> <p>Sodium perborate is mixed with a mixture, preferably a 1:1 mixture, of a rapid acetylating agent, e.g. TAED, and a slow acetylating agent, e.g. acetylsalicylic acid, in water to form a biocidally effective peracetic acid solution. When sodium perborate and TAED alone react in water, peracetic acid is produced quickly but has relatively little stability and a short useful life (curve 10). When sodium perborate and acetylsalicylic acid are mixed in water, the peracetic acid solution takes an extended duration to reach maximum efficacy, but is stable for an extended duration (curve 12). The mixture of rapid and slow acetylating agents quickly produces a stable peracetic acid concentration (curve 14).</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgystan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -

COLD STERILANT WITH EXTENDED ACTIVE LIFE**Background of the Invention**

The present invention relates to microbial decontamination arts. It finds particular application in conjunction with powdered sterilant concentrates which
5 react in room temperature water to form microcidally active compositions with an extended period of active life for field medical use and will be described with particular reference thereto. It is to be appreciated that the invention will also find application in conjunction with
10 other anti-microbial applications including biocidal compositions for use at elevated temperatures, biocidal compositions with other preselectable active durations, and the like.

Our earlier U.S. Letters Patent No. 5,116,575
15 describes a powdered anti-microbial composition which is ideally suited for use in automated liquid sterilization systems such as illustrated in the above-referenced U.S. Patent No. 4,892,706 or 5,217,698. The anti-microbial composition included two components which reacted in the
20 presence of water to form a strong oxidant. Preferably, acetylsalicylic acid and a perborate, such as sodium perborate, reacted to form peracetic acid. The powdered components further included anti-corrosive materials and buffers. The anti-corrosive materials inhibited corrosion
25 of brass, copper, aluminum, steel, and other materials commonly found in medical, dental, and surgical instruments. The buffers controlled the chemical reaction

- 2 -

and assisted in the corrosion inhibition. In particular, the preferred composition was formulated for optimum efficiency at 50° C. and to produce and maintain a peak peracetic acid concentration for the duration of the automated cycle, on the order of 1/2 hour.

Although the prior formulations were effective for their intended purpose, there is also a need for an anti-microbial formulation which reacts quickly in room temperature water, about 25° C., to produce an anti-microbially active solution for an extended period, on the order of eight hours. Such formulation should also inhibit corrosion and buffer pH to an optimal range.

An article by Death and Coates in the Journal of Clinical Pathology, Vol. 32, pp. 148-153 (1979) entitled "Effective pH on Sporicidal and Microbicidal Activity of Buffered Mixtures of Alcohol and Sodium Hypochlorite" noted superior microbicidal activity in a methanol/hypochlorite mixture and hypochlorite alone when buffered to a pH of about 7.6 - 8.1. An article by Melicherčíková in the Journal of Hygiene, Epidemiology, Microbiology, and Immunology, Vol. 33, No. 1, pp. 19-28 (1989) entitled "Disinfectant Effect of Persteril in Combination With Detergents" investigated shelf life of Perstil stabilized peracetic acid aqueous solutions. They proposed that peracetic acid should not be applied in combination with basic detergents because the sporicidal effect of peracetic acid was markedly declined at a pH of 9. In a paper by Hauthal, et al. in Tenside Surf. Det., Vol. 27, No. 3, pp. 187-193, entitled "Studies Concerning the Mechanism of Bleaching Activation", the effects of pH on bleaching activators diacetyl dioxohexahydrotriazine (DADHT) and tetraacetyl ethylene-diamine (TAED) in the formation of peroxyacetic acid with hydrogen peroxide or sodium perborate is investigated. This article notes that at higher pH values, the rate of peroxyacetic acid formation increases but becomes unstable, decomposing more rapidly to oxygen and acetic acid.

- 4 -

One advantage of the present invention is that it provides a composition which is mixable with available room temperature water to form an effective liquid microbicide.

Another advantage of the present invention is
5 that the resultant microbicide is stable and effective for an extended duration. This eliminates precise period of use criticality and facilitates use by less-skilled technicians.

Still further advantages of the present invention
10 will become apparent to those of ordinary skill in the art upon reading and understanding the following detailed description of the preferred embodiments.

Brief Description of the Drawings

The invention may take form in various components
15 and arrangements of components, and in various steps and arrangements of steps. The drawings are only for purposes of illustrating a preferred embodiment and are not to be construed as limiting the invention.

FIGURE 1 is a diagrammatic illustration of parts
20 per million of peracetic acid versus time for TAED, acetylsalicylic acid, and a blend of TAED and acetylsalicylic acid;

FIGURE 2 illustrates parts per million of
25 peracetic acid versus time for a blend of TAED and acetylsalicylic acid buffered to different pHs;

FIGURE 3 is a diagrammatic illustration of
peracetic acid versus time illustrating the effect of dropping the pH after the peracetic acid is initially formed.

Detailed Description of the Preferred Embodiments

30 A two compartment packet holds a powdered formulation including a perborate in one compartment and acetylizing agents in the other compartment. The compartments further hold a buffer for buffering the pH,

- 5 -

anti-corrosive materials, surfactants, sequestering agents, and the like.

The acetylizing agent includes a relatively rapid acetylizing agent, i.e. one producing two or more acetyl groups such as TAED. Preferably, the powdered TAED is a methylcellulose encapsulated form of TAED sold under the trademark MYKON™. As illustrated in curve 10 of FIGURE 1, the TAED and the perborate, such as a sodium perborate, react quickly in water to form a microbically effective concentration of peracetic acid, e.g. 2000 ppm. However, the concentration of peracetic acid tends to decrease relatively rapidly with time. On the other hand, as illustrated by curve 12, acetylsalicylic acid, a slower acetylating agent which produces only a single acetyl group, requires a relatively long duration to reach a maximum peracetic acid concentration. However, the peracetic acid produced with the acetylsalicylic acid acetylating agent is more stable and does not break down or degrade as fast. In order to obtain a rapid generation of a microbically effective concentration of peracetic acid yet stability over an extended duration, the TAED and the acetylsalicylic acid are mixed, preferably with a 1:1 molar ratio. As illustrated in curve 14, the peracetic acid solution produced from this mixture is more stable and is microbically effective over a longer duration than when formed with either the TAED or the acetylsalicylic acid taken alone.

Because 1 mole of TAED produces 2 moles of peracetic acid and 1 mole of acetylsalicylic produces 1 mole of peracetic acid, the preferred embodiment mixes 0.5 moles of TAED with 1 mole of acetylsalicylic acid to achieve the preferred 1:1 molar ratio. Appropriate amounts of sodium perborate, TAED, and acetylsalicylic acid are provided to generate 2,000 ppm peracetic acid or other biocidally effective amounts, in a preselected quantity of water. The composition further includes benzotriazoles or tolytriazoles or other compositions which inhibit copper

- 6 -

and brass corrosion in the presence of strong oxidizing compounds. Azoles, benzoates, and other five-membered ring compounds may also prove acceptable as copper and brass corrosion inhibitors. Phosphates provide pH buffering and
5 inhibit brass and iron corrosion. To inhibit the iron and steel corrosion, phosphates are present in a final concentration of at least 1.25% weight by volume in the resultant solution. For effective pH buffering, higher phosphonate concentrations can be provided. Molybdates,
10 chromates, dichromates, tungstates, vanadates, borates, and combinations thereof may be used in place of or in addition to the phosphates for iron and steel corrosion inhibition and for pH buffering.

The powdered composition preferably includes
15 hexametaphosphate or other sequestering agents for controlling calcium and magnesium salt precipitation in hard water. The sequestering agents further remove substance, e.g. cobalt, that inhibit the precursor reaction. Wetting agents or detergents are also present in
20 a concentration to form a 0.001% to 1.0% weight to volume concentration in the resultant solution.

Other acetyl donors are also contemplated, including diacetyl dihexahydratriazina (DADHT), sodium nanonoyl oxygenzene sulfonate, penta acetyl glucose (PAG),
25 and tetra acetyl glycouril (TAG) are also contemplated.

With reference to FIGURE 2, pH is observed to have a dramatic effect on the stability and life of the resultant solution. For the 1:1 TAED to acetylsalicylic acid preferred embodiment discussed above, a substantially
30 flat peracetic acid concentration curve 20 is achieved in the range of 1-8 hours for a pH of 8.3. As the pH increases to a pH of 8.51, the production rate of peracetic acid increases but the peracetic acid stability is reduced as illustrated in curve 22. As illustrated by curve 24,
35 when the pH is raised to 8.86, the initial peracetic acid production rate is increased still further, but the resultant solution becomes still more unstable over time.

- 7 -

As illustrated in FIGURE 3, high pHs are conducive to a rapid production of peracetic acid while lower, more nearly neutral pHs are conducive to long-term stability of the produced peracetic acid. In the
5 embodiment illustrated in FIGURE 3, TAED reacts with sodium perborate at a relatively high pH, e.g. pH=8.9, until the peracetic acid concentration approaches a maximum. The pH is then adjusted by adding or otherwise increasing the available amount of buffering agent in the solution. With
10 the pH dropped to about 7.5, as illustrated by curve 30, the peracetic acid concentration remains substantially stable. By distinction, as illustrated in curve 32, when and if the pH is not adjusted and permitted to decrease slowly from 8.9, the peracetic acid concentration decreases
15 reflecting the reduced stability.

The invention has been described with reference to the preferred embodiment. Obviously, modifications and alterations will occur to others upon reading and understanding the preceding detailed description. It is
20 intended that the invention be construed as including all such modifications and alterations insofar as they come within the scope of the appended claims or the equivalents thereof.

- 8 -

Having thus described the preferred embodiment, the invention is now claimed to be:

1. A powdered mixture in which a perborate, an acetyl donor, and a pH buffer react in water to form peracetic acid in an anti-microbial effective concentration, further characterized by the acetyl donor
5 including:

a mixture of a rapid acetyl donor which produces at least two acetyl groups and a slow acetyl donor which produces only a single acetyl group.

2. The mixture as set forth in claim 1 further characterized by the rapid acetyl donor being selected from the group consisting of TAED, methyl cellulose encapsulated TAED, tetra acetyl glycouril (TAG), penta acetyl glucose
5 (PAG), and mixtures thereof.

3. The mixture as set forth in claim 1 further characterized by the slow acetyl donor including acetylsalicylic acid.

4. The mixture as set forth in claim 1 further characterized by the pH buffer buffering the resultant peracetic acid solution to a pH between 7.5 and 8.5.

5. The mixture as set forth in claim 1 further characterized by the slow acetyl donor and the rapid acetyl donor being present in a 1:1 ratio.

6. A method of microbial decontamination in which an item to be microbially decontaminated is immersed in a solution formed by mixing water with a perborate, an acetylating agent, and a buffer to form a solution with a
5 biocidally effective concentration of peracetic acid, the method further characterized by:

- 9 -

the acetylating agent including a rapid acetylating agent which produces at least two acetyl groups and which rapidly causes a short term peracetic acid concentration peak, and a slow acetylating agent which produces only a single acetyl group and which slowly causes a long term peracetic acid concentration peak.

7. The method as set forth in claim 6 further characterized by the rapid acetylating agent including TAED, TAG, PAG, and mixtures thereof.

8. The method as set forth in claim 6 further characterized by the slow acetylating agent including acetylsalicylic acid.

9. The method as set forth in claim 6 further characterized by the resultant solution is buffered to a pH between 7.5 and 8.5.

10. The method as set forth in claim 6 further characterized by the pH being buffered to a pH greater than 8 during initial peracetic acid formation and after the peracetic acid concentration has substantially reached a peak, reducing the pH of the solution to about 7.5.

11. The method as set forth in claim 6 further characterized by the rapid and slow acetylating agents being present in a ratio of substantially 1:1.




FIG. 1




FIG. 2




FIG. 3

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 94/07726

<p>A. CLASSIFICATION OF SUBJECT MATTER IPC 6 A01N59/14 A01N37/16 //(A01N59/14, 37:44, 37:40, 37:16), (A01N37/16, 59:14, 37:44, 37:40)</p> <p>According to International Patent Classification (IPC) or to both national classification and IPC</p>														
<p>B. FIELDS SEARCHED</p> <p>Minimum documentation searched (classification system followed by classification symbols) IPC 6 A01N</p> <p>Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched</p> <p>Electronic data base consulted during the international search (name of data base and, where practical, search terms used)</p>														
<p>C. DOCUMENTS CONSIDERED TO BE RELEVANT</p> <table border="1"> <thead> <tr> <th>Category *</th> <th>Citation of document, with indication, where appropriate, of the relevant passages</th> <th>Relevant to claim No.</th> </tr> </thead> <tbody> <tr> <td>X</td> <td> US,A,3 969 257 (L.T.MURRAY) 13 July 1976 see column 2, line 66 - column 3, line 10 see column 3, line 22 - column 4, line 16 see column 5, line 18 - line 56 see column 5, line 63 --- </td> <td>1,3-5</td> </tr> <tr> <td>X</td> <td> LU,A,78 578 (SCHÜLKE & MAYR) 20 April 1978 see page 1, line 38 - page 4, line 33 see page 5, line 30 - line 40 see page 6, line 21 - line 24 --- </td> <td>1-4,6-9</td> </tr> <tr> <td>X</td> <td> EP,A,0 186 052 (INTEROX) 2 July 1986 see page 5, line 3 - line 11 see page 7, line 7 - line 9 see page 9, line 16 - line 17 see page 10, line 16 --- -/-- </td> <td>1,2,4,6, 7,9</td> </tr> </tbody> </table>			Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	X	US,A,3 969 257 (L.T.MURRAY) 13 July 1976 see column 2, line 66 - column 3, line 10 see column 3, line 22 - column 4, line 16 see column 5, line 18 - line 56 see column 5, line 63 ---	1,3-5	X	LU,A,78 578 (SCHÜLKE & MAYR) 20 April 1978 see page 1, line 38 - page 4, line 33 see page 5, line 30 - line 40 see page 6, line 21 - line 24 ---	1-4,6-9	X	EP,A,0 186 052 (INTEROX) 2 July 1986 see page 5, line 3 - line 11 see page 7, line 7 - line 9 see page 9, line 16 - line 17 see page 10, line 16 --- -/--	1,2,4,6, 7,9
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.												
X	US,A,3 969 257 (L.T.MURRAY) 13 July 1976 see column 2, line 66 - column 3, line 10 see column 3, line 22 - column 4, line 16 see column 5, line 18 - line 56 see column 5, line 63 ---	1,3-5												
X	LU,A,78 578 (SCHÜLKE & MAYR) 20 April 1978 see page 1, line 38 - page 4, line 33 see page 5, line 30 - line 40 see page 6, line 21 - line 24 ---	1-4,6-9												
X	EP,A,0 186 052 (INTEROX) 2 July 1986 see page 5, line 3 - line 11 see page 7, line 7 - line 9 see page 9, line 16 - line 17 see page 10, line 16 --- -/--	1,2,4,6, 7,9												
<p><input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.</p>														
<p>* Special categories of cited documents :</p> <table border="0"> <tr> <td style="vertical-align: top;"> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </td> <td style="vertical-align: top;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </td> </tr> </table>			<p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p>	<p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p>										
<p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p>	<p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p>													
<p>Date of the actual completion of the international search</p> <p style="text-align: center;">28 September 1994</p>		<p>Date of mailing of the international search report</p> <p style="text-align: center;">1 1. 10. 94</p>												
<p>Name and mailing address of the ISA</p> <p>European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+ 31-70) 340-3016</p>		<p>Authorized officer</p> <p style="text-align: center;">Lamers, W</p>												

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 94/07726

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DE,A,28 17 858 (SCHÜLKE & MAYR) 25 October 1979 see claim 1 see page 10, line 10 see page 10, line 18 see page 13, line 17 see page 16, paragraph 2 see page 17, paragraph 3 see page 18, paragraph 3 ----	1,2,4,6, 7,9
A	DATABASE WPI Week 9225, Derwent Publications Ltd., London, GB; AN 91-181525 [25] & JP,A,3 109 499 (NIPPON PEROXIDE) 9 May 1991 see abstract ----	1-11
A	DE,A,36 15 787 (FRESENIUS) 12 November 1987 see claims 1,3,4 ----	1-11
A	FR,A,2 090 369 (HENKEL) 14 January 1972 see the whole document ----	1-11
A	JOURNAL FÜR PRAKTISCHE CHEMIE CHEMIKER-ZEITUNG, vol.334, April 1992, HEIDELBERG DE pages 293 - 297 J.HOFMANN ET AL. 'Bleaching Activators and the Mechanism of Bleaching Activation' see the whole document -----	1-11

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 94/07726

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A-3969257	13-07-76	US-A- 4120809	17-10-78
LU-A-78578	20-04-78	DE-A- 2701133	20-07-78
		BE-A- 861167	16-03-78
		CH-A- 631869	15-09-82
		FR-A, B 2377203	11-08-78
		GB-A- 1566671	08-05-80
		NL-A- 7800463	17-07-78
		SE-B- 440846	26-08-85
		SE-A- 7714473	14-07-78
EP-A-0186052	02-07-86	FR-A- 2574424	13-06-86
		JP-A- 61179300	11-08-86
DE-A-2817858	25-10-79	NONE	
DE-A-3615787	12-11-87	NONE	
FR-A-2090369	14-01-72	DE-A- 2026240	09-12-71
		AT-A, B 309694	15-07-73
		BE-A- 767734	29-11-71
		CA-A- 948102	28-05-74
		CH-A- 566786	30-09-75
		GB-A- 1337858	21-11-73
		NL-A- 7107082	01-12-71
		SE-B- 401448	16-05-78
		DE-A- 2112485	12-10-72